Radcliffe & CardioNerds @AHA22: Reduction of Triglycerides With Pemafibrate скачать в хорошем качестве

Radcliffe & CardioNerds @AHA22: Reduction of Triglycerides With Pemafibrate

Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/?... Dr Gurleen Kaur, Director of the CardioNerds Internship (Brigham and Women's Hospital, US) joins us in this collaboration between the @CardioNerds and Radcliffe Cardiology to interview Dr Aruna Pradhan (Brigham and Women's Hospital, US), study director of the PROMINENT trial on the late-breaking data from AHA 2022. PROMINENT was a multicenter randomized trial aiming to determine whether pemafibrate (K-877) would delay cardiovascular events in diabetes patients. Patients received either two 0.2mg tablets of pemafibrate, or a placebo daily. The study showed that pemafibrate was not associated with a reduction in adverse cardiovascular events. Recorded remotely from Boston, 2022. This content is intended for healthcare professionals only. Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.